A comparison of CAS9 proteins derived from different organisms in a dendritic cell - t cell (DC-t) cell proliferation assay as well as an antigen presenting assay (also called a MHC associated peptide…
Ended Definitive Contract Awarded
- Contract number
- 75F40122C00175
- Awardee
-
Proimmune, Inc. UEI C97DJ9NYBGV9
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $53,487
Award facts
- Contract value 100% obligated
- $53,487.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
Award details come from SAM.gov/FPDS.
About this award
Proimmune, Inc. was awarded a definitive contract by the Department of Health and Human Services' Food and Drug Administration (FDA) to conduct a comparison of CRISPR-associated protein 9 (Cas9) derived from different organisms. Specifically, the contract calls for Proimmune to perform a dendritic cell-T cell proliferation assay and an antigen presenting assay, also known as major histocompatibility complex class II-associated peptide proteomics assay, to analyze Cas9 proteins. The potential value of the contract is $53,487. No set-aside designation was used for this award. The period of performance is from September 2022 through September 2023, with all work to be conducted in Silver Spring, Maryland. Proimmune will leverage its expertise in immunology research and services to complete the technical evaluations required by this FDA contract.
Description
A comparison of CAS9 proteins derived from different organisms in a dendritic cell - t cell (DC-t) cell proliferation assay as well as an antigen presenting assay (also called a MHC associated peptide proteomics (mapps) assay).
Quick answers
Who was awarded contract 75F40122C00175?
75F40122C00175 was awarded to Proimmune, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 20, 2022.
How much is contract 75F40122C00175 worth?
The government has obligated $53,487 on 75F40122C00175.
Was contract 75F40122C00175 competed?
The extent of competition for 75F40122C00175 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award